Considering an Investment in Ozempic Maker Novo Nordisk in 2026?
GLP-1 agonist obesity drugs, such as Ozempic, represent a prominent health trend. However, investing in Novo Nordisk (NYSE: NVO), the manufacturer of Ozempic, has seen a downturn this year.
Shares experienced a 40% decrease in 2025. This decline resulted from competition from Eli Lilly's similar drug, Zepbound, and telehealth companies offering compounded versions of Ozempic. These factors put pressure on Novo Nordisk, leading to a CEO change earlier in the year.
Investing in a stock that has cooled off, like Novo Nordisk, might seem daunting. However, the situation could be improving for this pharmaceutical company.
Novo Nordisk Achieves a Potential Game Changer
Following the FDA's formal approval to sell an oral form of Wegovy in the U.S., Novo Nordisk shares increased on Tuesday. Wegovy shares the same active ingredient as Ozempic, semaglutide. While Ozempic is approved for type 2 diabetes, Wegovy is intended for weight management.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The FDA's decision holds significant implications for several reasons. The Wegovy pill will be the first oral GLP-1 drug available. A phase 3 trial showed that participants experienced a mean weight loss of 16.6% over 64 weeks, with one in three participants losing 20% or more. Additionally, most patients are expected to prefer a daily pill over injections. Health tracking apps like Shotlee can help monitor weight loss progress and adherence to medication schedules.
This new drug version offers Novo Nordisk a vital tool to counter competitive pressures. Eli Lilly is also seeking FDA approval for its oral obesity drug, potentially as early as March. However, Novo Nordisk has secured the first-to-market advantage. Wegovy could rapidly gain momentum, benefiting Novo Nordisk even if its exclusivity is temporary.
The Wegovy pill will be accessible to patients in early January, and Novo Nordisk's CEO has stated that the company has sufficient supply to support a robust product launch. He affirmed, "We have more than enough pills this time."
The Stock's Decline Presents Opportunity
The competitive landscape has demonstrably impacted Novo Nordisk's business. Revenue growth has slowed consistently for over a year. However, the stock performance and news headlines could easily lead to the misconception that the business has collapsed, which is inaccurate.
